<DOC>
	<DOC>NCT01836133</DOC>
	<brief_summary>This multicenter, observational study will evaluate the efficacy and safety of Tarceva (erlotinib) in patients with locally advanced or metastatic adenocarcinoma non-small cell lung cancer and an ECOG performance status of 0-1. Eligible patients receiving Tarceva according to the Summary of Product Characteristics and local label will be followed for the duration of their treatment.</brief_summary>
	<brief_title>An Observational Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Histologically or cytologically confirmed, locally advanced (Stage IIIb) or metastatic (Stage IV) adenocarcinoma nonsmall cell lung cancer Eastern Cooperative Oncology Group (ECOG) performance status 01 Adequate hematologic, renal and liver function Patient initiating treatment with Tarceva according to the Summary of Product Characteristics Any contraindications to treatment with Tarceva according to the Summary of Product Characteristics and local label Any other malignancies within the previous 5 years, except for in situ carcinoma of the cervix and basal and squamous cell carcinoma of the skin Previous systemic anticancer treatment with HER1/EGFR inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>